All Articles
Meet your cancer care team and learn about their unique roles in your care. Read More ›
Your nurse navigator will be with you through each phase of your treatment. Start your relationship by asking these questions. Read More ›
How data collected from patients in routine
clinical practice are driving improvements
in the management of multiple myeloma Read More ›
No one is ready for the initial shock that comes with a diagnosis of cancer. The feelings that accompany a cancer diagnosis may be difficult to imagine beforehand, challenging to process as you hear and attempt to accept the news, and impossible to appreciate fully if you are not the individual who has just been diagnosed. Read More ›
When you are first diagnosed with cancer, including multiple myeloma, you probably have many questions. You may ask: Do I have a multiple myeloma specialist close to my home? If not, am I able to travel? Should I consider participating in a clinical trial if I am eligible and my doctor recommends it? Read More ›
Since you were diagnosed with multiple myeloma, you have undoubtedly heard and read all kinds of advice about how you should be treated. Your friends, loved ones, and work colleagues—your support team—as well as your treatment team, which includes your doctors, nurses, social workers, navigators, and other professionals, have so much information and advice to share. They all want to help you choose the course of action that is right for you. Read More ›
One of the many things that you probably did after receiving a diagnosis of multiple myeloma was to select a doctor and care team. They helped you to learn about multiple myeloma and how to navigate the complexities of treatment decision-making. Read More ›
After the shock of being diagnosed with multiple myeloma wore off, you have learned a new “language” related to cancer and multiple myeloma care, you have likely read and talked about treatment options, and you may have already started treatment. You may have also joined a support group. Read More ›
The chemotherapy-free combination of venetoclax plus obinutuzumab has shown efficacy and tolerability in older patients with chronic lymphocytic leukemia. Adding acalabrutinib, a new targeted agent, may enhance the clinical benefits of this regimen, according to results of a clinical trial. Read More ›
Cancer specialists are now able to use a new scoring system to decide when to start treatment for patients who have been diagnosed with chronic lymphocytic leukemia. Read More ›

